flexible Food and Drug Administration has once again rescued a biotech company seeking a drug approval based on flawed clinical trial data.

Alexion Pharma (ALXN) won agreement from FDA on Monday to expand the use of its top-selling, ultra-orphan medicine Soliris to treat patients with myasthenia gravis, a rare neuromuscular disease. FDA approved the Soliris label expansion even though the phase 3 clinical trial just missed its primary endpoint.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.